ライフサイエンスコーパス: autologous transplant

1 unger patients by high-dose melphalan and an autologous transplant.

2 -matched transplant, and one had received an autologous transplant.

3 ollowed by HLA-matched related allogeneic or autologous transplant.

4 autologous, and 597 (67%) received unpurged autologous transplants.

5 ymphomas, including some that relapsed after autologous transplants.

6 Seventeen patients had previous autologous transplant; 6 were in complete remission, and

7 FMT relieved symptoms compared with placebo (autologous transplant), although the effects decreased o

8 f 48 such patients: mean age 47.7 years, 52% autologous transplant and 67% peripheral stem cell sourc

9 ons for allogeneic transplantation vis-a-vis autologous transplant and to discuss the rationale and p

10 fractory to both; (31 [70%]) had received an autologous transplant, and (30 [62%]) had high-risk cyto

11 reviously reported, and that early onset and autologous transplant are favorable prognostic indicator

12 tic alternative for patients relapsing after autologous transplant, but induction of a remission is t

13 sone, cytarabine, and cisplatin (DHAP), with autologous transplant consolidation for those with chemo

14 ide, and dexamethasone induction followed by autologous transplant, consolidation, and maintenance.

15 In humans, autologous transplants derived from bone marrow (BM) usu

16 Our previous work in patients undergoing autologous transplant for multiple myeloma (MM) or breas

17 for all race and ethnicity groups; however, autologous transplant for multiple myeloma was highest f

18 was intubated, had an allogeneic rather than autologous transplant, had an infection or gastrointesti

19 e assessed the role of thymic function after autologous transplant in adults, correlating serial comp

20 e is growing evidence for the role of tandem autologous transplant in breaking refractory disease.

21 Supporting the potential for autologous transplants in Hirschsprung disease, we obser

22 39 +/- 6 mm(3); n = 13), similar to those of autologous transplanted iNOS(+/+) mice (39 +/- 4 mm(3);

23 2 mm(3); n = 13; mean +/- SE) compared with autologous transplanted iNOS(-/-) mice (24 +/- 3 mm(3);

24 ion therapy with a quadruplet regimen before autologous transplant is the standard of care.

25 A review of the data on tandem vs sequential autologous transplants is provided.

26 Because gene therapy represents an autologous transplant, it obviates immune suppression be

27 Although autologous transplants may prolong survival, most patien

28 o studies of vitrified vessel segments in an autologous transplant model showed no adverse effects of

29 For patients relapsing after autologous transplant, more recent analyses have reporte

30 on and remodeling, suggesting the utility of autologous transplant of bone marrow-derived mononuclear

31 of predicted (P = .0002), allogeneic versus autologous transplant (P = .0003), diffusion capacity of

32 ation relating to 19412 allogeneic and 17950 autologous transplant patients.

33 l death were associated with higher costs in autologous transplant recipients ($18,400 and $20,500, r

34 However, allogeneic and autologous transplant recipients each had distinctive ri

35 tment category and was most pronounced among autologous transplant recipients.

36 opoietic recovery in both the allogeneic and autologous transplant settings.

37 py" approaches with stem cell or bone marrow autologous transplants still have not found a role in th

38 After autologous transplant, the donor genotype from lentiviru

39 Similarly, autologous transplant utilization for lymphoma was simil

40 Dynamics of MDS-PA at diagnosis and after autologous transplant were evaluated in 86 of 285 patien

41 Three autologous transplants were performed with CD34+ cell fr

42 ) were assessed in 10 patients who underwent autologous transplants with stem cells, cryopreserved in